Feature | February 18, 2009| Nick Obradovich

Web Exclusive: How CT Perfusion Stacks Up Against SPECT, Angiography

Frank Rybicki, M.D. is the director of cardiac CT and vascular CT, MRI, Brigham and Womens Hospital

Frank Rybicki, M.D., director of cardiac CT and vascular CT, MRI, Brigham and Women’s Hospital, sat down with Imaging Technology News (ITN) to talk about the Toshiba-sponsored Core-320 trial that will compare coronary CT angiography with myocardial perfusion performed on Toshiba’s Acquilion ONE against traditional invasive angiography and SPECT. The trial is set to begin later this year.

ITN: What are the clinical questions that you hope Core 320 will answer?

Dr. Rybicki: Core 320 is designed to evaluate CT in a new way. CT, in the heart, gives morphology data...anatomy and coronary imaging. It has pretty good spatial resolution and pretty good temporal resolution, and of course, it's noninvasive. In many cases at the end of the CT scan, there are still several unanswered questions. The major hypothesis of Core 320 is that the perfusion data provides added information to morphology.

ITN: Do you have an expectation going into the Core 320 on how CT will perfusion will stack up against SPECT and catheter angiography?

Dr. Rybicki: Everyone that is involved in this has high expectations. Everyone in the community is pulling for a CT system, like a wide area detector system, to do good functional imaging and do good perfusion. rk. Having all those expectations is wonderful, but you really have to roll up your sleeves in terms of proving it. You can do all you want in a small, single-center study, but the proof will be in a multi-centered and multi-national evalution.

ITN: You’ve had experience with the Aquilion ONE. Most clinicians are impressed with the spatial and temporal resolution. What has been your experience with the perfusion component?

Dr. Rybicki: The perfusion component is still in evaluation. The perfusion images I've seen to date are very good technical quality, but perfusion CT is still not a clinical tool. It has to be emphasized that using any scanner, including the
Aquilion ONE for perfusion and relying on the presence or absence of a perfusion
abnormality is in the realm of clinical research . The AquilionONE makes great
morpholic images, gives good radiation levels and it can be a used for wide
variety of things. We suspect there are good things to come.

ITN: What still needs to be worked on or corrected with CT perfusion?

Dr. Rybicki: It is hard to say because CT is so new and both modalities are attacking perfusion from different angles. In SPECT, we introduce a radioisotope that goes to the heart, then radiation is emitted from the heart out and detected by a detector system. CT is totally different. You're putting the radiation outside
through and then detecting on a system.

ITN: With CTA vs. catheter angiography, you measure the positive and negative predictive values. How do you measure CT perfusion’s performance versus SPECT?

Dr. Rybicki: One way it to partition the heart muscle CT and SPECT images into segments, and then analyze each on a segment-by-segment basis. There is also a so called "bullseye" or polar map to do this kind of image analysis. These maps are also used by some imagers for diagnoses

Patients with severe disease can be managed with catheter-based intervention or surgery. SPECT is currently a key tool to separate patients. Perfusion is one piece of the puzzle used to make that distinction. If perfusion imaging, SPECT and perhaps CT in the future, suggests that there is significant myocardium that poorly perfused by viable, this is very valuable information for revascularization management. On the flip side, if the patient has a large perfusion deficit and all the tissue is dead, a large, expensive, and potentailly dangerous surgical intervention is not needed. For quite some time people have been searching for one modality that can perform these functions, and we hope that 320-detector row CT is a large incremental step in this direction.

ITN: If CT with perfusion performs well in this trial, could it be expanded to target a greater patient population rather than just low- to medium- risk patients?

Dr. Rybicki: It's unlikely that one test can do everything for all patients. Any vendor would like to be able to cover a great number of the patient population. The coronary CT part is still going to be limited by calcium. That's not going to go away with the 320. I suspect that [CT with perfusion] will still be suited for low and intermediate risk patients.

ITN: Even with the 320, heavily calcified arteries still present imaging problems for CT?

Dr. Rybicki: Absolutely. That's not going to change. One thing that would be really nice is that if you have an artery that is calcifed with multiple low-grade lesions, having a normal perfusion CT, if it were to validate that, would be very useful.

Related Content

coronary CT angiography, CCTA, SCOT-HEART trial substudy, SCCT
News | Computed Tomography (CT)| April 26, 2016
The results of a secondary analysis of the SCOT-HEART trial show that coronary computed tomography angiography (CCTA)...
Toshiba, Aquilion Lightning CT, 50 kW generator, FDA clearance
News | Computed Tomography (CT)| April 20, 2016
April 19, 2016 — Toshiba America Medical Systems Inc.’s Aquilion Lightning...
FFR-CT, heartflow
Feature | CT Angiography (CTA)| April 15, 2016 | Jeff Zagoudis
Fractional flow reserve-computed tomography (FFR-CT) is still in the early stages of clinical implementation in the U
TAVR runoff image

A 3-D CT reconstruction of a TAVR run-off image to assess the femoral access route using Toshiba's Aquillion One and Vital Images advanced visualization technologies. 

Feature | Heart Valve Repair| April 15, 2016
April 15, 2016 — Accurate and precise anatomical information is crucial to successful transcatheter aortic valve repl
computed tomography, CT scans, electronic medical devices, interference, FDA
News | Computed Tomography (CT)| April 13, 2016
The U.S. Food and Drug Administration (FDA) has received a small number of reports of adverse events that are believed...
Sponsored Content | Videos | CT Angiography (CTA)| April 12, 2016
A discussion on the adoption rate of FFR-CT with Dr. Campbell Rogers, chief medical officer of HeartFlow.
FFR-CT, HeartFlow, PLATFORM trial, one-year results, ACC 2016
News | CT Angiography (CTA)| April 05, 2016
Novel technology developed by HeartFlow Inc. significantly reduces the need for invasive procedures to diagnose...
Toshiba, ACC 2016, American College of Cardiology, CT, MR, ultrasound, angiography, interventional radiology

Infinix 4-D CT image courtesy of Toshiba America Medical Systems.

News | Cardiac Imaging| March 30, 2016
Toshiba America Medical Systems Inc. announced it would demonstrate the following diagnostic imaging technologies at...
University of Tennessee, Mobile Stroke Unit, CT angiography, Siemens Somatom Scope
News | Stroke| March 23, 2016
The University of Tennessee College of Medicine in Memphis introduced a new, comprehensive Mobile Stroke Unit, capable...
Neovasc, Tiara, transcatheter mitral valve, TMVR

Transcatheter mitral valve technology was among the most popular content on the DAIC website in 2015. Pictured is the Neovasc Tiara transcatheter mitral valve, which is currently in clinical trials.

Feature | March 22, 2016 | Dave Fornell
DAIC readers chose the following stories as the most popular content in 2015, based on website analytics.
Overlay Init